Pfizer (PFE) : Nn Investment Partners Holdings N.v. reduced its stake in Pfizer by 6.05% during the most recent quarter end. The investment management company now holds a total of 7,675,362 shares of Pfizer which is valued at $278,692,394 after selling 494,107 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Jul 13, 2016.Pfizer makes up approximately 2.56% of Nn Investment Partners Holdings N.v.’s portfolio.
Other Hedge Funds, Including , Braver Wealth Management reduced its stake in PFE by selling 4,545 shares or 3.59% in the most recent quarter. The Hedge Fund company now holds 122,089 shares of PFE which is valued at $4,433,052. Pfizer makes up approx 0.74% of Braver Wealth Management’s portfolio.Factory Mutual Insurance Co reduced its stake in PFE by selling 167,000 shares or 6.44% in the most recent quarter. The Hedge Fund company now holds 2,425,897 shares of PFE which is valued at $88,084,320. Pfizer makes up approx 1.13% of Factory Mutual Insurance Co’s portfolio.Stillwater Investment Management boosted its stake in PFE in the latest quarter, The investment management firm added 1,490 additional shares and now holds a total of 69,183 shares of Pfizer which is valued at $2,498,890. Pfizer makes up approx 1.41% of Stillwater Investment Management’s portfolio.Edge Wealth Management reduced its stake in PFE by selling 12,240 shares or 3.94% in the most recent quarter. The Hedge Fund company now holds 298,269 shares of PFE which is valued at $10,773,476. Pfizer makes up approx 4.42% of Edge Wealth Management’s portfolio.Iowa State Bank boosted its stake in PFE in the latest quarter, The investment management firm added 2,835 additional shares and now holds a total of 120,757 shares of Pfizer which is valued at $4,361,743. Pfizer makes up approx 2.21% of Iowa State Bank’s portfolio.
Pfizer closed down -0.13 points or -0.35% at $36.64 with 1,69,14,164 shares getting traded on Monday. Post opening the session at $36.69, the shares hit an intraday low of $36.55 and an intraday high of $36.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Investors should note that on Jun 23, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Sep 1, 2016.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.